Movement Alert|EVEREST MED falls 4.01% in Regular Trading, wet AMD trial progress offers limited support

Market Focus11-20 09:41

On November 20, EVEREST MED fell 4.01% in Regular Trading, trading at HK$22.04, with turnover of HK$19.715 million.

The latest disclosed development was the first patient dosed in the Phase 2b ASCEND trial of VIS-101 for wet age-related macular degeneration, but the update reflects an early-stage clinical milestone with no immediate earnings contribution, limiting near-term support for the shares.

Company disclosures indicate the China study plans to enroll about 244 patients and compares 6 mg and 9 mg VIS-101 against 2 mg aflibercept given every eight weeks, with results intended to support dose selection for global Phase 3 trials. The stock had also recently reacted to medical insurance inclusion news for two products and the renewal of another, making the latest R&D progress less effective as a fresh trading driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment